NCT06659653 is a EARLY_PHASE1 clinical trial of PRG2302 in Acute Lymphoblastic Leukemia, sponsored by Tan Jie.

Who is sponsoring NCT06659653?

NCT06659653 is sponsored by Tan Jie.

What drugs are being tested in NCT06659653?

Interventions in NCT06659653: PRG2302.

What condition does NCT06659653 study?

NCT06659653 studies Acute Lymphoblastic Leukemia.

Is NCT06659653 still recruiting?

NCT06659653 is currently recruiting now. Last updated 26 October 2024.

Last reviewed 2024-10-26 · How we verify

NCT06659653

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

Recruiting now EARLY_PHASE1 Last updated 26 October 2024

What this trial tests

EARLY_PHASE1 trial testing PRG2302 in Acute Lymphoblastic Leukemia in 18 participants. Currently enrolling.

Timeline

24 May 2024

Primary endpoint
31 March 2027

31 March 2028

Quick facts

Lead sponsor	Tan Jie
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	24 May 2024
Primary completion	31 March 2027
Estimated completion	31 March 2028
Sites	1 location across China

Drugs / interventions tested

PRG2302 — full drug profile →

Conditions studied

Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →

Sponsor

Tan Jie — full company profile →

Who can join

Adults 18 to 70, any sex, with Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Clinical Study on the Safety and Effectiveness of CD19/CD22 Chimeric Antigen Receptor T Cells in the Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT05621291 — A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Follo · NA · recruiting
NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
NCT07479927 — Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06659653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tan Jie
Last refreshed: 26 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06659653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing